Mechanisms of Action of Non-Steroidal Anti-Inflammatory Drugs for the Prevention of Alzheimer's Disease

被引：66

作者：

Cole, Greg M. ^{[1
,2
]}

Frautschy, Sally A. ^{[1
,2
]}

机构：

[1] Greater Los Angeles Healthcare Syst, Geriatr Res & Educ Ctr, Vet Adm, North Hills, CA 91343 USA

[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90048 USA

来源：

CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS | 2010年 / 9卷 / 02期

关键词：

Alzheimer's disease; cyclooxygenases; non-steroidal anti-inflammatory drugs; docosahexaenoic acid; curcumin; AMYLOID PRECURSOR PROTEIN; MILD COGNITIVE IMPAIRMENT; TRANSGENIC MOUSE MODEL; CEREBROSPINAL-FLUID; ANIMAL-MODEL; DOUBLE-BLIND; A-BETA; CONTROLLED-TRIAL; DOWNS-SYNDROME; TAU PATHOLOGY;

D O I：

10.2174/187152710791011991

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Alzheimer's disease (AD) is accompanied by an activation of the innate immune system, and many epidemiological studies have shown reduced risk for dementia or AD associated with chronic consumption of non-steroidal anti-inflammatory drugs (NSAIDS). These observations led to animal model studies to test the hypothesis that NSAIDs can be disease-modifying for some aspects of AD pathogenesis. NSAIDS cannot only suppress inflammatory targets, which could contribute to neuroprotection, they also slow amyloid deposition by mechanisms that remain unclear. Several large clinical trials with NSAID therapies with AD subjects have failed, and cyclooxygenase-2 does not appear to be a useful target for disease modifying therapy. However, there may be apolipoprotein E E4 pharmacogenomic effects and a real but delayed positive signal in a large primary prevention trial with naproxen. This encourages researchers to re-address possible mechanisms for a stage-dependent NSAID efficacy, the subject of this review.

引用

页码：140 / 148

页数：9

共 100 条

[1] Rofecoxib in patients with mild cognitive impairment: Further analyses of data from a randomized, double-blind, trial [J].

Aisen, Paul S. ;

Thal, Leon J. ;

Ferris, Steven H. ;

Assaid, Christopher ;

Nessly, Michael L. ;

Giuliani, Michael J. ;

Lines, Christopher R. ;

Norman, Barbara A. ;

Potter, William Z. .

CURRENT ALZHEIMER RESEARCH, 2008, 5 (01) :73-82

[2] The inflammatory hypothesis of Alzheimer disease: Dead or alive? [J].

Aisen, Paul S. .

ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2008, 22 (01) :4-5

[3] Inflammation and Alzheimer's disease [J].

Akiyama, H ;

Barger, S ;

Barnum, S ;

Bradt, B ;

Bauer, J ;

Cole, GM ;

Cooper, NR ;

Eikelenboom, P ;

Emmerling, M ;

Fiebich, BL ;

Finch, CE ;

Frautschy, S ;

Griffin, WST ;

Hampel, H ;

Hull, M ;

Landreth, G ;

Lue, LF ;

Mrak, R ;

Mackenzie, IR ;

McGeer, PL ;

O'Banion, MK ;

Pachter, J ;

Pasinetti, G ;

Plata-Salaman, C ;

Rogers, J ;

Rydel, R ;

Shen, Y ;

Streit, W ;

Strohmeyer, R ;

Tooyoma, I ;

Van Muiswinkel, FL ;

Veerhuis, R ;

Walker, D ;

Webster, S ;

Wegrzyniak, B ;

Wenk, G ;

Wyss-Coray, T .

NEUROBIOLOGY OF AGING, 2000, 21 (03) :383-421

[4]

Alafuzoff Irina, 2000, Journal of Alzheimer's Disease, V2, P37

[5] Drebrin A is a postsynaptic protein that localizes in vivo to the submembranous surface of dendritic sites forming excitatory synapses [J].

Aoki, C ;

Sekino, Y ;

Hanamura, K ;

Fujisawa, S ;

Mahadomrongkul, V ;

Ren, Y ;

Shirao, T .

JOURNAL OF COMPARATIVE NEUROLOGY, 2005, 483 (04) :383-402

[6] Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology [J].

Arvanitakis, Z. ;

Grodstein, F. ;

Bienias, J. L. ;

Schneider, J. A. ;

Wilson, R. S. ;

Kelly, J. F. ;

Evans, D. A. ;

Bennett, D. A. .

NEUROLOGY, 2008, 70 (23) :2219-2225

[7] Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease [J].

Bard, F ;

Cannon, C ;

Barbour, R ;

Burke, RL ;

Games, D ;

Grajeda, H ;

Guido, T ;

Hu, K ;

Huang, JP ;

Johnson-Wood, K ;

Khan, K ;

Kholodenko, D ;

Lee, M ;

Lieberburg, I ;

Motter, R ;

Nguyen, M ;

Soriano, F ;

Vasquez, N ;

Weiss, K ;

Welch, B ;

Seubert, P ;

Schenk, D ;

Yednock, T .

NATURE MEDICINE, 2000, 6 (08) :916-919

[8] Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology [J].

Bard, F ;

Barbour, R ;

Cannon, C ;

Carretto, R ;

Fox, M ;

Games, D ;

Guido, T ;

Hoenow, K ;

Hu, K ;

Johnson-Wood, K ;

Khan, K ;

Kholodenko, D ;

Lee, C ;

Lee, M ;

Motter, R ;

Nguyen, M ;

Reed, A ;

Schenk, D ;

Tang, P ;

Vasquez, N ;

Seubert, P ;

Yednock, T .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (04) :2023-2028

[9] Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease [J].

Begum, Aynun N. ;

Jones, Mychica R. ;

Lim, Giselle P. ;

Morihara, Takashi ;

Kim, Peter ;

Heath, Dennis D. ;

Rock, Cheryl L. ;

Pruitt, Mila A. ;

Yang, Fusheng ;

Hudspeth, Beverly ;

Hu, Shuxin ;

Faull, Kym F. ;

Teter, Bruce ;

Cole, Greg M. ;

Frautschy, Sally A. .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 326 (01) :196-208

[10] Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort [J].

Breitner, J. C. S. ;

Haneuse, S. J. P. A. ;

Walker, R. ;

Dublin, S. ;

Crane, P. K. ;

Gray, S. L. ;

Larson, E. B. .

NEUROLOGY, 2009, 72 (22) :1899-1905

← 1 2 3 4 5 6 7 8 9 10 →